GENB Stock Forecast: Generate Biomedicines, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Generate Biomedicines, Inc. hold a median 12-month price target of $27 — +183.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 0 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Generate Biomedicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (23): Analysts have, on balance, been raising their forecasts.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
GENB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GENB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +183.0% from it.
Of the 12 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | Morgan Stanley | Maintains | Overweight | $22 → $21 |
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $30 |
| 8 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $30 |
| 28 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $25 → $30 |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | $20 → $22 |
| 8 May 2026 | HC Wainwright & Co. | Maintains | Buy | $16 → $25 |
| 13 Apr 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 24 Mar 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 24 Mar 2026 | Goldman Sachs | Initiates | Buy | — |
| 24 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 24 Mar 2026 | Morgan Stanley | Initiates | Overweight | — |
| 24 Mar 2026 | Piper Sandler | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GENB.
This page is one stock. Monday covers all of them.
GENB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
GENB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GENB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 60.7×
- Price / book
- 3.4×
- EV / EBITDA
- —
Cheaper than 4% of US stocks
Cheaper than 27% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −75.6%
- Dividend yield
- —
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Generate Biomedicines, Inc. has a market value of $1.3B and an enterprise value of $1.0B.
Generate Biomedicines, Inc. employs 312 people.
Data provided by Twelve Data
GENB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at GENB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Generate Biomedicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about GENB
What is the GENB stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Generate Biomedicines, Inc. have a median 12-month price target of $27, with estimates ranging from $21 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GENB stock a buy right now?
Of the 5 analysts covering Generate Biomedicines, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Generate Biomedicines, Inc. 0 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GENB?
As at 21 Nov 2026, Generate Biomedicines, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (23 of 100).
Will GENB stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +183.0% from the last close, and Ticker Nerd's factor model ranks Generate Biomedicines, Inc. 0 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GENB stock forecast for 2030?
No analyst covering Generate Biomedicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GENB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $30 over the next 12 months.
What does Generate Biomedicines, Inc. do?
Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using machine learning and generative biology to design novel protein therapeutics. The company’s Generate Platform combines computational design with biological engineering to create medicines across multiple protein-based modalities, including antibodies, enzymes, cytokines, peptides, and cell therapies.
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using machine learning and generative biology to design novel protein therapeutics. The company’s Generate Platform combines computational design with biological engineering to create medicines across multiple protein-based modalities, including antibodies, enzymes, cytokines, peptides, and cell therapies. Its pipeline includes investigational programs such as GB-0895 for severe asthma, GB-4362, and GB-5267, reflecting its emphasis on developing treatments for complex and hard-to-address diseases. Based in Somerville, Massachusetts, Generate Biomedicines operates at the intersection of artificial intelligence, drug discovery, and therapeutic development, serving as a platform-driven innovator in modern biomedicine.
CEO Mr. Michael T. Nally M.B.A. · 312 employees · United States · https://generatebiomedicines.com